$OCSAW

Oculis presents Phase 2 data for Privosegtor, an FDA Breakthrough-designated optic neuritis therapy showing improved visual acuity and reduced nerve damage, advancing toward Phase 3 registration trial.

Oculis presents Phase 2 ACUITY trial results for Privosegtor at neuro-ophthalmology conference, showing vision improvements. Breakthrough therapy advances to registrational PIONEER program.

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.

Oculis files 2025 audited financial statements with SEC via Form 20-F and announces investor conference participation, signaling transparent capital markets engagement.

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.